Skip to content

The Effect of Norepinephrine Versus Dopamine in Renal Transplant Recipients on Postoperative Graft Function

The Effect of Norepinephrine Versus Dopamine in Renal Transplant Recipients on Postoperative Graft Function

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03107858
Enrollment
44
Registered
2017-04-11
Start date
2017-11-01
Completion date
2019-11-01
Last updated
2017-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Transplant

Brief summary

Renal transplantation is now recognized as a treatment of choice for patients with chronic renal failure with end-stage renal disease. Renal transplantations are associated with better quality of life, better cost/benefit ratio, and possibly longer survival. Significant changes in blood pressure are common throughout the surgical procedure for kidney transplantation. All efforts are made to maintain an appropriate level of blood pressure by using an adequate intravascular volume and vasopressor administration. All efforts are made to maintain an appropriate level of blood pressure by using an adequate intravascular volume and vasopressor administration. All efforts are made to maintain an appropriate level of blood pressure by using an adequate intravascular volume and vasopressor administration. All efforts are made to maintain an appropriate level of blood pressure by using an adequate intravascular volume and vasopressor administration.

Interventions

DRUGNorepinephrine

Norepinephrine infusion will be used at a starting dose of 0.05μg/kg/min. Dose range: 0.05 -0.15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative

DRUGDopamine

Dopamine infusion will be used at a starting dose of 5μg/kg/min. Dose range: 5 -15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients scheduled for a living donor kidney transplantation

Exclusion criteria

* Patients (less than 18 years old) * Patients' refusal of consenting for enrolment in the study

Design outcomes

Primary

MeasureTime frameDescription
serum creatininefour hours postoperativelypostoperative

Secondary

MeasureTime frameDescription
renal artery blood flowfour hours postoperativelyMeasured postoperative through renal artery Doppler
blood ureafour hours postoperativelypostoperative
urine outputover 24 hourspostoperative
renal artery diameterfour hours postoperativelyMeasured postoperative through renal artery Doppler

Countries

Egypt

Contacts

Primary ContactAhmed Elkadi, MBBC
ahmedkader333@gmail.com+201007485190

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026